Skip to main content

Hand Dermatitis

Dermatology
3
Pipeline Programs
2
Companies
6
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket

Dermatology is a $292M market that is mature and consolidating, dominated by a single blockbuster approaching loss of exclusivity.

$0.292B marketMature→ Stable30 products15 companies

Key Trends

  • HUMIRA (adalimumab) dominates 88% of market spending but faces LOE in near-term, creating vulnerability
  • Novel mechanisms like aryl hydrocarbon receptor agonists gaining traction with emerging products in peak lifecycle
  • Substantial clinical trial activity (812 trials) suggests ongoing innovation pipeline despite mature market

Career Verdict

Dermatology offers stable near-term opportunities but requires strategic positioning given patent cliff risk and limited market size compared to other therapeutic areas.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1HUMIRADeclining
$258M
AbbVie·LOE_APPROACHING
#2VTAMAGrowing
$19M
Merck & Co.·PEAK13.5yr
#3ORACEADeclining
$4M
Galderma·LOE_APPROACHING1.6yr

Drug Class Breakdown

Unknown Mechanism (predominantly HUMIRA)
$258M(88%)

Patent cliff looming

Aryl Hydrocarbon Receptor Agonists
$19M(6%)

Emerging innovation

Retinoids and Derivatives
$3M(1%)

Mature segment

Other Mechanisms
$12M(4%)

Niche applications

Career Outlook

Stable

Dermatology represents a stable but narrow career path with limited growth compared to larger therapeutic areas; compensation is competitive in Commercial and Medical Affairs but R&D opportunities are scarce. HUMIRA's patent cliff creates near-term uncertainty for AbbVie but may drive restructuring and new product launches elsewhere. Market consolidation around a few large players (AbbVie, Regeneron, Merck) limits startup/biotech opportunities.

Breaking In

Enter via Commercial or Medical Affairs roles where hiring is highest; dermatology has lower scientific barrier to entry than oncology but requires strong relationship-building and market access acumen.

For Experienced Professionals

Leverage HUMIRA transition expertise or develop specialty in emerging mechanisms (retinoids, AhR agonists); consider moving to larger franchises (immunology, oncology) if seeking higher growth trajectory.

In-Demand Skills

Health Economics & Outcomes Research (HEOR)Dermatology Clinical KnowledgeSales Strategy & Account ManagementDigital Health / Telemedicine IntegrationMedical Writing for Topicals & Systemics

Best For

Regional Sales ManagerMedical Science Liaison (MSL)Product Manager (Post-Launch)Health Economics ManagerRegulatory Affairs Specialist

Hiring Landscape

$85K-$386K

Dermatology shows concentrated hiring at AbbVie (52 positions) and Regeneron (46 positions), with Commercial roles dominating (89 jobs, $188K avg salary) and Medical Affairs roles commanding premium compensation ($386K avg). Limited R&D hiring (8 positions) suggests mature drug development phase with emphasis on commercialization and market access.

173
Open Roles
3
Companies Hiring
3
Departments

Top Hiring Companies

53Growing
46Growing
14Stable

By Department

Commercial(51%)
$188K
Medical Affairs(24%)
$386K
Research & Development(5%)

Commercial and Medical Affairs roles offer strong compensation and growth, but overall job market is small; best for professionals seeking revenue-generating functions rather than discovery roles.

On Market (1)

Approved therapies currently available

PANRETINApproved
alitretinoin
Unknown Company
Retinoid [EPC]topical1999
965K Part D

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Afecta Pharmaceuticals
1 program
1
AFX5931Phase 41 trial
Active Trials
NCT03703895Completed20Est. Apr 2019
Basilea Pharmaceutica
Basilea PharmaceuticaSwitzerland - Allschwil
1 program
1
alitretinoinPhase 35 trials
Active Trials
NCT01407679Terminated7Est. Apr 2014
NCT00519675Completed150
NCT00309621Completed250Est. May 2007
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Afecta PharmaceuticalsAFX5931
Basilea Pharmaceuticaalitretinoin
Basilea Pharmaceuticaalitretinoin
Basilea Pharmaceuticaalitretinoin
Basilea Pharmaceuticaalitretinoin
Basilea Pharmaceuticaalitretinoin

Clinical Trials (6)

Total enrollment: 1,762 patients across 6 trials

A Study for a Topical Medication Versus Placebo in Patients With Hand Dermatitis

Start: Sep 2018Est. completion: Apr 201920 patients
Phase 4Completed

Alitretinoin in the Treatment of Chronic Hand Eczema

Start: May 2007150 patients
Phase 3Completed

Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis

Start: Apr 2006Est. completion: May 2007250 patients
Phase 3Completed

Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis

Start: Mar 2005Est. completion: Feb 2007300 patients
Phase 3Completed

Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis

Start: Dec 2004Est. completion: Sep 20071,035 patients
Phase 3Completed

Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus

Start: Aug 2011Est. completion: Apr 20147 patients
Phase 2Terminated

Related Jobs in Dermatology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.